KaloBios Pharma pulls plug on asthma drug, shares plunge – Reuters

KaloBios Pharma pulls plug on asthma drug, shares plunge
Reuters
(Reuters) – Shares of KaloBios Pharmaceuticals Inc fell nearly 50 percent in extended trade after the company said it would stop developing an asthma drug that failed in a mid-stage study. The drug, KB003, failed to bring about a clinically meaningful 
KaloBios stock slides; to stop asthma studyMarketWatch
KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma StudyRTT News

all 19 news articles »

View full post on asthma – Google News